HomeKyowa Kirin Co., Ltd.

Trade Kyowa Kirin Co., Ltd. - 4151 CFD

Market is not available at the momentMarket information is presented
as of 2026-11-20T06:07:00+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread5.7
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.01444 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.01444%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.00778 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.00778%
Overnight funding adjustment time22:00 (UTC)
CurrencyJPY
Min traded quantity1
Margin10.00%
Stock exchangeJapan
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close2573.6
Open2541.9
1-Year Change-16.62%
Day's Range2530.9 - 2569.6

Trade Kyowa Kirin Co., Ltd. - 4151

Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready